Tampere, Finland – 12 February 2025: Neuro Event Labs Oy today announced it has raised a €2.0M financing round from new investor Catalyze Capital as well as existing investor Hadean Ventures, and others. The proceeds will support commercial expansion in Europe as well as entry into the US market for its lead product Nelli®.
Neuro Event Labs Oy, based in Tampere, Finland, is a health technology company dedicated to AI motion diagnostics in Neurology, developing products that improve diagnosis, and thereby treatment, of neurological conditions. The lead product Nelli® is an AI-powered diagnostics and monitoring device for epilepsy, providing doctors with high-quality data of seizures based on video and audio recordings that can be collected in either the patient’s home or in a hospital environment.
With over 65 million patients suffering worldwide, epilepsy is one of the most common neurological diseases. The majority of these patients could become seizure-free with appropriate treatment following a proper diagnosis, and with clear characterization of the disease the misdiagnosis rates can be improved.
Nelli® unlocks objective, accurate detection and characterization of seizures in a cost-effective and patient-convenient manner. This enables the best possible treatment for epilepsy patients, significantly increasing the chance of becoming seizure-free.
“The positive impact this has on the daily lives of these patients is invaluable, while at the same time Nelli® also decreases the costs of care for epilepsy patients. Therefore, Catalyze Capital is excited to join the existing investors of Neuro Event Labs to further accelerate the growth and commercial roll-out of Nelli.” says Benjamin Sieters, Investment Director at Catalyze Capital.
Nelli® is CE-marked and recently received EU MDR certification. The product has been launched in several European countries for daily clinical care in epilepsy and is also used by multiple pharmaceutical companies in their clinical studies to adequately evaluate the efficacy of (new) anti-epileptic treatments. US market entry is expected later this year.
“With this financing round, and the support of our investors, we will be able to further extend our foothold in the international epilepsy market in our aim of providing access to Nelli® for epilepsy patients all across Europe and the US,” comments Kaapo Annala, CEO of Neuro Event Labs.
About Neuro Event Labs Oy
Neuro Event Labs is a Finnish medical technology growth company. The company’s main product, Nelli®, monitors epilepsy patients at home and in hospital. Accurate epilepsy seizure data is collected, analyzed and relayed to the patient’s physician, who makes individual treatment decisions based on the reports. The solution has been developed in close cooperation with leading epilepsy researchers and clinicians.
https://www.neuroeventlabs.com
About Hadean Ventures
Hadean Ventures is a European life science fund manager that invests in life science companies across Europe with a particular focus on the Nordic region. Hadean Ventures is managing funds backed by leading European and US-based, private and institutional investors. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world-class academic institutions and start-up hubs across the region.
https://www.hadeanventures.com
About Catalyze Capital
Catalyze Capital is a venture capital firm investing in early-stage companies that apply science an technology to develop innovations that will positively impact people’s lives and the planet’s health. Operating from Amsterdam, the Netherlands, Catalyze Capital focuses on European companies active in high-tech sectors, including the Life Science, Sustainable and Deep Tech sectors.
https://catalyze-capital.com/
Contact
Kaapo Annala, CEO, Neuro Event Labs Oy
[email protected]